瘤细胞异质性驱动了瘤内免疫反应的空间组织
Miho Tanaka1, Lotus Lum1, Kenneth H Hu2,3
1Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
The Journal of experimental medicine
|April 1, 2025
概括
内异质性 (ITH) 是免疫治疗失败的驱动因素. 寒冷的瘤细胞产生免疫抑制的微环境,损害T细胞的局部和瘤范围的功能,即使在治疗后.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 瘤内异质性 (ITH),以瘤内的遗传和细胞多样性为特征,与免疫疗法耐药性和抗瘤免疫力低下有关.
- 了解ITH的空间动态对于开发有效的癌症治疗至关重要.
研究的目的:
- 研究异质瘤中不同瘤细胞群体对局部免疫微环境和抗瘤免疫反应的影响.
- 阐明冷瘤细胞影响免疫细胞功能和免疫治疗结果的机制.
主要方法:
- 模拟包含热 (富含T细胞) 和冷 (缺乏T细胞) 瘤种群的异质瘤.
- 使用光标签,精确地跟踪瘤细胞群和免疫细胞的空间.
- 瘤微环境的空间分析,以评估免疫细胞透,巨细胞表型 (CD206Hi) 和T细胞功能.
- 研究CX3CL1在冷瘤区域中调解免疫抑制中的作用.
主要成果:
- 寒冷瘤细胞群在混合异质瘤中产生"主导寒冷"效应.
- 瘤细胞创造了独特的局部微环境;冷瘤细胞的区域表现出明显的免疫抑制.
- 冷瘤区域显示CD206Hi巨细胞增加和局部T细胞功能减弱.
- 寒冷区域的T细胞活性受损在免疫治疗后持续存在,并且由寒冷瘤细胞产生的CX3CL1介导.
结论:
- 异质瘤中的冷瘤细胞群在瘤范围和局部空间尺度上显著降低了抗瘤免疫力.
- 针对由冷瘤细胞驱动的免疫抑制机制可能是克服异质瘤免疫疗法耐药性的策略.
相关概念视频
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
01:27Tumor Immunotherapy
432
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
432
02:40Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K